Posted on January 20th, 2012 by
At the JP Morgan Healthcare Conference in San Francisco on Monday, Medtronic CEO Omar Ishrak once again laid out his three-pronged effort to rejuvenate medical device maker Medtronic (NYSE:MDT): improving execution, optimizing medical device innovation and quickly expanding its global footprint…But a recent Mayo Clinic study based on the use of Sapien raises questions about market adoption. The Mayo study found that doctors require many procedures before becoming proficient in using transcatheter aortic valve replacement therapy.
MedCity News, by Arundhati Parmar, 1/10/2012
You must be logged-in to the site to post a comment.